


Provectus Pharmaceuticals, Inc (Thu, May 02, 2024)

Buy candidate since Apr 17, 2024

Gain 0.68%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **2.21**

#/ 30045

Trend: Buy
MV Long: Buy
MV Short: Sell
Pivot: Sell
Volume: Buy
MACD: Buy

Tech commentaries:

The **Provectus Pharmaceuticals, Inc** stock price fell by **-1.85%** on the last day (Thursday, 2nd May 2024) from **\$0.195** to **\$0.191**. It has now fallen 3 days in a row. During the last trading day the stock fluctuated **3.48%** from a day low at **\$0.191** to a day high of **\$0.198**. The price has fallen in 5 of the last 10 days and is down by **-1.9%** for this period. Volume has increased on the last day by **88 thousand** shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, **169 thousand** shares were bought and sold for approximately **\$32.36 thousand**.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise **32.00%** during the next 3 months and, with a 90% probability hold a price between **\$0.214** and **\$0.329** at the end of this 3-month period.

The **Provectus Pharmaceuticals, Inc** stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$0.196**. On a fall, the stock will find some support from the long-term average at approximately **\$0.186**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Friday, March 15, 2024**, and so far it has fallen **-11.79%**. Further fall is indicated until a new bottom pivot has been found. **Provectus Pharmaceuticals, Inc** gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

On the downside, the stock finds support just below today's level from accumulated volume at **\$0.180** and **\$0.170**. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$0.199**, **\$0.200** and **\$0.213**.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved **\$0.0067** between high and low, or **3.48%**. For the last week, the stock has had daily average volatility of **4.00%**.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for **Provectus Pharmaceuticals, Inc** stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy candidate.

Risk: **High**

Evaluation: **Buy Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.